Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMHRG8Q)

Drug Name
Carbidopa Drug Info
Synonyms
Atamet; Carbidopum; Lodosin; Lodosyn; Methyldopahydrazine; Stalevo; Carbidopa Monohydrate; Carbidopa anhydrous; Carbidopa hydrate; Carbidopum monohydricum; MK 486; Alpha-Methyldopahydrazine; C-126; C-DOPA; Carbidopa (anhydrous); Carbidopum [INN-Latin]; Lodosyn (TN); Lodosyn, Carbidopa; MK-485; MK-486; N-Aminomethyldopa; Carbidopa [USAN:INN:BAN]; Carbidopa-1-wasser; Hadrazino-alpha-methyldopa; L-alpha-Methyldopahydrazine; Carbidopa, (S)-Isomer; Carbidopa, Entacapone, & Levodopa; S(-)-CARBIDOPA; S-(-)-Carbidopa; L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate; Alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid; L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid; L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid; L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid; S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid; Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S); KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID; Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid; (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate; (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid-water (1/1); (S)-(-)-carbidopa; (S)-(-)-carbidopa hydrate; (S)-alpha-Hydrazino-3,4-dihydroxy-alpha-methyl-benzenepropanoic acid monohydrate; (S)-carbidopa; (S)-carbidopahydrate; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid; (alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
Therapeutic ClassAntiparkinson Agents
Cross-matching ID
PubChem CID
34359
ChEBI ID
CHEMBL1201236
CAS Number
CAS 28860-95-9
TTD Drug ID
D0P7JZ
ACDINA Drug ID
D00098

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Long-term depression 1.83 6.98e-2 55/60 (91.67%) GRIA2;PRKCB;GNAS;...
Basal transcription factors 1.60 4.40e-1 37/45 (82.22%) TAF9B;GTF2H4;GTF2H3;...
Sulfur metabolism 1.58 3.47e-1 9/10 (90%) SELENBP1;SUOX;ETHE1
Fc gamma R-mediated phagocytosis 1.56 2.95e-1 79/97 (81.44%) PAK1;PRKCB;CRK;...
PPAR signaling pathway 1.55 2.47e-1 66/74 (89.19%) CYP27A1;HMGCS2;FABP6;...
Mucin type O-glycan biosynthesis 1.55 2.08e-1 20/36 (55.56%) GALNT6;GALNT12;B4GALT5;...
Herpes simplex virus 1 infection 1.41 5.91e-1 165/498 (33.13%) HLA-F;TNFRSF14;IFNGR2;...
Nicotine addiction 1.34 6.62e-1 32/40 (80%) GRIA2;SLC17A7;CACNA1A;...
Type I diabetes mellitus 1.33 6.58e-1 38/43 (88.37%) HLA-F;CPE;HLA-DQA1;...
Proteasome 1.32 6.12e-1 44/46 (95.65%) PSMB8;PSMC6;PSMA6;...
Necroptosis 1.30 6.68e-1 113/159 (71.07%) CHMP4A;PPID;GLUL;...
ErbB signaling pathway 1.29 6.35e-1 79/85 (92.94%) PAK1;PRKCB;AREG;...
Renin-angiotensin system 1.29 6.21e-1 20/23 (86.96%) ANPEP;CPA3;ENPEP;...
Natural killer cell mediated cytotoxicity 1.29 5.87e-1 99/131 (75.57%) PAK1;PRKCB;KRAS;...
Leishmaniasis 1.29 5.54e-1 67/77 (87.01%) PRKCB;NCF2;IFNGR2;...
Ribosome biogenesis in eukaryotes 1.28 5.34e-1 52/108 (48.15%) NOP56;CSNK2A2;LSG1;...
Caffeine metabolism 1.28 5.08e-1 5/6 (83.33%) NAT1;CYP2A6;NAT2
Nucleotide excision repair 1.26 5.47e-1 40/47 (85.11%) RFC5;GTF2H4;GTF2H3;...
Gap junction 1.25 5.75e-1 72/88 (81.82%) PRKCB;GNAS;GUCY1A1;...
Vitamin digestion and absorption 1.24 5.57e-1 17/24 (70.83%) SLC5A6;APOA1;SLC19A1;...
Renal cell carcinoma 1.22 6.25e-1 68/69 (98.55%) PAK1;CRK;PAK6;...
Allograft rejection 1.21 6.22e-1 32/38 (84.21%) HLA-F;HLA-DQA1;HLA-C;...
Other types of O-glycan biosynthesis 1.20 6.25e-1 29/47 (61.7%) GALNT6;GALNT12;GALNT7
Base excision repair 1.20 6.07e-1 29/33 (87.88%) FEN1;PCNA;PARP2;...
Asthma 1.19 6.03e-1 25/31 (80.65%) HLA-DQA1;FCER1G;HLA-DPA1;...
One carbon pool by folate 1.18 6.23e-1 15/20 (75%) ALDH1L1;TYMS;MTHFS;...
Graft-versus-host disease 1.18 6.07e-1 32/42 (76.19%) HLA-F;HLA-DQA1;HLA-C;...
Pyrimidine metabolism 1.17 6.48e-1 40/56 (71.43%) CANT1;NME4;DCK;...
Amphetamine addiction 1.16 6.51e-1 57/69 (82.61%) GRIA2;PRKCB;GNAS;...
VEGF signaling pathway 1.06 6.73e-1 50/59 (84.75%) PRKCB;CDC42;KRAS;...
Parkinson disease -1.29 4.31e-1 176/249 (70.68%) ATP5F1C;SNCAIP;PSMD11;...
Chemical carcinogenesis -1.30 4.33e-1 186/281 (66.19%) CYP2E1;KPNA2;GSTA4;...
Porphyrin and chlorophyll metabolism -1.31 4.35e-1 23/43 (53.49%) UGT2B4;HMOX2;CP;...
Starch and sucrose metabolism -1.33 4.20e-1 25/36 (69.44%) PGM1;G6PC3;PYGM;...
Mitophagy -1.33 4.30e-1 56/68 (82.35%) PINK1;RELA;ATF4;...
Metabolism of xenobiotics by cytochrome P450 -1.33 4.34e-1 49/77 (63.64%) UGT2B4;CYP3A5;GSTM1;...
Proteoglycans in cancer -1.33 4.36e-1 172/205 (83.9%) ANK3;WNT5A;ARHGEF1;...
Calcium signaling pathway -1.40 4.03e-1 213/240 (88.75%) MCOLN1;EDNRB;CASQ1;...
Thyroid hormone signaling pathway -1.41 3.76e-1 112/121 (92.56%) MED13;ATP1A1;NCOR1;...
Amoebiasis -1.41 3.89e-1 99/102 (97.06%) COL4A2;IFNG;IL10;...
Citrate cycle (TCA cycle) -1.42 3.97e-1 30/30 (100%) PCK2;SUCLA2;MDH2;...
Malaria -1.43 3.88e-1 44/50 (88%) THBS3;ACKR1;KLRB1;...
Glycolysis / Gluconeogenesis -1.44 3.80e-1 56/67 (83.58%) ALDH9A1;PDHB;ADPGK;...
Vascular smooth muscle contraction -1.45 3.84e-1 113/133 (84.96%) MYLK;ITPR2;PLCB3;...
Estrogen signaling pathway -1.46 3.72e-1 119/137 (86.86%) HRAS;ITPR2;KRT9;...
Apelin signaling pathway -1.49 3.18e-1 117/137 (85.4%) PDE3B;ADCY3;SMAD2;...
Central carbon metabolism in cancer -1.49 3.34e-1 67/70 (95.71%) HKDC1;HK1;PKM;...
Fatty acid elongation -1.50 3.22e-1 19/27 (70.37%) ACOT7;HADHA;TECR;...
Regulation of lipolysis in adipocytes -1.51 3.41e-1 52/55 (94.55%) INSR;PDE3B;ADCY3;...
Vibrio cholerae infection -1.52 3.22e-1 44/50 (88%) KDELR1;SEC61B;KCNQ1;...
Cardiac muscle contraction -1.52 3.48e-1 64/87 (73.56%) ATP1B3;CACNG4;RYR2;...
Biosynthesis of unsaturated fatty acids -1.55 3.02e-1 21/27 (77.78%) ELOVL1;HACD2;ELOVL5;...
Galactose metabolism -1.56 3.04e-1 26/31 (83.87%) GLB1;GALT;PGM1;...
Arrhythmogenic right ventricular cardiomyopathy -1.57 3.15e-1 70/77 (90.91%) CACNA1D;LAMA2;CACNA2D2;...
Glucagon signaling pathway -1.58 3.57e-1 89/107 (83.18%) ATF4;PCK2;G6PC3;...
Protein processing in endoplasmic reticulum -1.65 2.38e-1 127/171 (74.27%) HSP90AB1;FBXO2;NPLOC4;...
Hypertrophic cardiomyopathy -1.66 2.82e-1 81/90 (90%) SGCB;MYL3;TPM3;...
Pentose phosphate pathway -1.75 1.54e-1 25/30 (83.33%) G6PD;PGM1;ALDOC;...
Ether lipid metabolism -1.76 2.00e-1 32/49 (65.31%) PLPP1;GDPD3;CEPT1;...
Dilated cardiomyopathy -1.79 3.00e-1 86/96 (89.58%) SGCB;MYL3;TPM3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 15uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H